2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1412

Vascular Cell Adhesion Molecule (VCAM-1) and Angiostatin in Systemic Lupus Erythematosus
Abstract Number: 701

Vascular Differences Associated to Genetic Polymorphisms of Endothelial Nitric Oxide Synthase in Mexican Patients with Systemic Sclerosis. A Preliminary Report
Abstract Number: 703

Vascular Ischemic Events in Systemic Sclerosis – A Cross-Sectional Comparision with Population-based Controls
Abstract Number: 1423

Vascular Thrombosis and Pregnancy Morbidity in Patients with Systemic Lupus Erythematosus with Positive Antiphospholipid Profile and Thrombocytopenia
Abstract Number: 1686

Vertebral Fracture Assessment-Detected Abdominal Aortic Calcification Enhances Cardiovascular Disease Risk Stratification of Rheumatoid Arthritis Patients
Abstract Number: 13

Visfatin/Nampt in Osteoarthritis: Sites of Production in Human Joints and Role of Its Enzymatic Activity
Abstract Number: 2356

Visual Manifestations in Giant Cell Arteritis : Trend Over Five Decades
Abstract Number: 1019

Visualization of Cartilage in High-Resolution Magnetic Resonance Imaging Is a New Imaging Biomarker for the Quantification of Joint Damage in Rheumatoid Arthritis
Abstract Number: 2245

Vitamin D Deficiency Is Associated with, but Does Not Predict, Change in hsCRP in Systemic Lupus Erythematosus (SLE)
Abstract Number: 1390

Vitamin D Deficiency Is Not Associated with Nor Does It Predict Progression of Coronary Artery Calcium or Carotid Intima-Media Thickness in Systemic Lupus Erythematosus
Abstract Number: 1179

Vitamin D Receptor Polymorphisms Are Associated with Clinical Outcomes and IgM Responses to Common Pathogens but Not Baseline Disease Activity in Early Inflammatory Arthritis
Abstract Number: 1251

Vulnerability Features Are Common in Coronary Plaques of Asymptomatic Patients with Rheumatoid Arthritis Compared to Controls: Associations with Lipid and Oxidative Stress Biomarkers
Abstract Number: 2547

Weekly Subcutaneous Abatacept Confers Comparable Onset of Treatment Response and Magnitude of Efficacy Improvement Over 6 Months When Administered with or without an Intravenous Abatacept Loading Dose
Abstract Number: 2533

Weight Loss Is Associated with Structure Modification in Subjects with Radiographic Osteoarthritis of the Knee: Data From the Osteoarthritis Initiative
Abstract Number: 2375

WHAT Affects the Quality of Life in Patients with BEHCET’S Disease?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].